Subject: IRAS 203355 Amendment Categorisation and Implementation Information

From: "AMENDMENTS, Hra (HEALTH RESEARCH AUTHORITY)" < hra.amendments@nhs.net>

Date: 10/08/17 09:04

To: Carl Reynolds <carl.reynolds@imperial.ac.uk>
CC: "jrco@imperial.ac.uk" <jrco@imperial.ac.uk>, "NRSPCC, Nhsg (NHS GRAMPIAN)" <nhsg.nrspcc@nhs.net>,

"'research-permissions@wales.nhs.uk'" <research-permissions@wales.nhs.uk>

# Amendment Categorisation and Implementation Information

## Dear Dr Reynolds

Thank you for submitting an amendment to your project.

If you have participating NHS/HSC organisations in any other UK nations that are affected by this amendment we will forward the information to the relevant national coordinating function(s).

Please note that you may only implement changes described in the amendment notice.

#### What Happens Next?

### Information Specific to Participating NHS Organisations in England

- 1. This email also constitutes HRA Approval for the amendment, and you should not expect anything further from the HRA.
- 2. You may implement this amendment immediately.
- 3. You should ensure that participating NHS organisations in England are informed of this amendment. In doing so, you should include the NHS R&D Office, LCRN (where applicable) as well as the local research team.
- 4. Participating NHS organisations in England should prepare to implement this amendment, where expected.

## Information Specific to Participating NHS/HSC Organisations in Northern Ireland, Scotland and/or Wales

- 1. You may implement this amendment immediately
- 2. You do not need to inform the R&D offices, as we have separately made it available via their national coordinating functions.
- 3. Participating NHS/HSC organisations should prepare to implement this amendment, where expected.

IRAS Project ID:	203355
Short Study Title:	Idiopathic Pulmonary Fibrosis Job Exposures Study (IPF JES)
Date complete amendment submission received:	7 August 2017
Sponsor Amendment Reference Number:	Non Substantial Amendment 1 (AM02)
Sponsor Amendment Date:	7 August 2017
Amendment Type	Non Substantial
Outcome of HRA Assessment	This email also constitutes HRA Approval for the amendment, and you should not expect anything further from the HRA.
For NHS/HSC R&D Office information	
Amendment Category	С

If you have any questions relating to the wider HRA approval process, please direct these to hra.approval@nhs.net

If you have any questions relating this amendment in one of the devolved administrations, please direct these to the relevant national coordinating function

Additional information on the management of amendments can be found in the IRAS guidance.

Please do not hesitate to contact me if you require further information.

Kind regards

1 of 2 26/09/17 09:47

## Kirstren



Kirsten Peck HRA Approval Amendment Coordinator

## **Health Research Authority**

Level 3
Block B
Whitefriars
Lewins Mead
Bristol
BS1 2NT
T. 02071048051
E. kirsten.peck@nhs.net
W. www.hra.nhs.uk

IMPORTANT - Click here for the latest details of the roll-out of HRA Approval in England

The HRA is keen to know your views on the service you received – our short feedback form is available here

This message may contain confidential information. If you are not the intended recipient please inform the

sender that you have received the message in error before deleting it.

Please do not disclose, copy or distribute information in this e-mail or take any action in relation to its contents. To do so is strictly prohibited and may be unlawful. Thank you for your co-operation.

NHSmail is the secure email and directory service available for all NHS staff in England and Scotland. NHSmail is approved for exchanging patient data and other sensitive information with NHSmail and other accredited email services.

For more information and to find out how you can switch, https://portal.nhs.net/help/joiningnhsmail

-Attachments:

17 EM 0021 AM02 ChecklistDownload-2017-08-10-08 54 39.zip

4.1 MB

2 of 2 26/09/17 09:47